It hasn't been easy being Amarin over the last several months. The Irish drugmaker ($AMRN) slammed into one obstacle after another. New chemical entity status for the key ingredient in its cardiovascular drug Vascepa? No, says the FDA. Permission to market the drug to vast numbers of new patients? No again.
But now, Amarin doesn't have to walk that rough road alone. Kowa Pharmaceuticals' U.S. unit has signed up to help market Vascepa, the triglyceride-fighting pill derived from fish oil. And that means almost three times as many sales reps will be peddling the Vascepa message.
That's good, given that Amarin slashed its sales force back in October, when an FDA advisory panel voted against a broader label for Vascepa. Read more from FiercePharmaMarketing>>
-- Tracy Staton (email | Twitter)